Medtide

Medtide FCF/Debt

The Free Cash Flow to Debt Ratio of Medtide (3880.HK) as of Nov 5, 2026 is 14.41 %. In the previous year, Free Cash Flow to Debt Ratio was 6.03 % — a change of 138.95% (higher).

FCF/Debt

14.41 %

YoY

138.95%

Last updated:

Free Cash Flow to Debt Ratio of Medtide is 2024 14.41 % . Free Cash Flow to Debt Ratio of Medtide was 2023 6.03 % . It decreases by 138.95% higher compared to the previous year.

The Medtide FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2021
28.88 CNY
Jan 1, 2022
8.20 CNY
Jan 1, 2023
6.03 CNY
Jan 1, 2024
14.41 CNY
The Medtide FCF/Debt history
YEARFCF/DebtYoY
14.41 %+138.95%
6.03 %-26.48%
8.20 %-71.60%
28.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide, Inc. generates revenue through peptide-focused contract research, development, and manufacturing services. The company offers CRO services for peptide new chemical entity (NCE) discovery and synthesis, alongside CDMO services covering peptide chemistry, manufacturing, and control (CMC) development and commercial production. Its primary clients are pharmaceutical companies seeking active pharmaceutical ingredients (APIs) rather than finished drug products, with services delivered across domestic and overseas markets. The firm's revenue streams are derived from these specialized peptide-related R&D and manufacturing contracts. Medtide's business model centers on providing comprehensive peptide development and manufacturing solutions, including CMC filing support for clients. The company's services target the API segment of the pharmaceutical industry, focusing on peptide-based drug development rather than final drug formulations. This specialization allows Medtide to serve clients requiring high-quality peptide synthesis and manufacturing capabilities for their drug development pipelines. The company's revenue is generated through direct contracts with pharmaceutical firms for peptide-related services, including discovery synthesis, CMC development, and commercial manufacturing. These services are delivered to clients operating in both domestic and international markets, with the firm emphasizing its expertise in peptide chemistry and manufacturing processes. Medtide's business model relies on its ability to provide end-to-end peptide development and manufacturing solutions to pharmaceutical clients. Medtide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medtide stock

Free Cash Flow to Debt Ratio of Medtide is 14.41 % in 2024.

Free Cash Flow to Debt Ratio of Medtide changed from 6.03 % to 14.41 %, representing a 138.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Medtide since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Medtide with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Medtide

All Key Metrics — Medtide